Bioventus Scoops Up Misonix In $518M Stock & Cash Deal; Raises FY21 Sales Outlook
See more from Benzinga
Icosavax Kicks Off NASDAQ Debut; Trading Almost 150% Higher On IPO Price Of
Atreca Stock Selloff Triggered By Interim ATRC-101 Data Appears Overdone, Stifel Says
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.